Electromed Inc. (NYSEMKT:ELMD) sells a competitive medical device meant for airway clearance. This medical device is analogous to what Baxter delivers in the peritoneal dialysis market, only for airway clearance. Electromed has launched a new model and is seeing accelerated revenue growth. Electromed is also near attaining profitability. Electromed, Inc. (NYSEMKT:ELMD) net profit margin is -12.80% and weekly performance is 14.18%. On last trading day company shares ended up $1.45. Analysts mean target price for the company is $2.75. Electromed, Inc. (NYSEMKT:ELMD) distance from 50-day simple moving average (SMA50) is 16.10%.
On June 12, 2014, with the recommendation of the Compensation Committee of the Board of Directors of Biocept, Inc. (NASDAQ:BIOC), the Board of Directors of the Company (the “Board”) approved the issuance of 44,496 restricted stock units, or RSUs, of the Company to its Chief Executive Officer, Michael Nall, pursuant to its 2013 Equity Incentive Plan. Biocept Inc. (NASDAQ:BIOC) shares advanced 7.91% in last trading session and ended the day on $7.23. BIOC return on assets is -391.80%.Biocept Inc. (NASDAQ:BIOC) quarterly performance is -2.69%.
Aldeyra Therapeutics Inc (NASDAQ:ALDX) has named a new Chief Financial Officer, who will assume his position on June 23. The company noted that the new executive will help the company in its financial dealings through the clinical trials because he has widespread experience in the area. Aldeyra Therapeutics Inc. (NASDAQ:ALDX) shares moved up 12.26% in last trading session and was closed at $7.51, while trading in range of $7.32 – $8.22. Aldeyra Therapeutics Inc. (NASDAQ:ALDX) year to date (YTD) performance is 4.31%.
Newport Beach-based Aerie Pharmaceuticals Inc. (NASDAQ:AERI) said on 12 June that former Advanced Medical Optics founder James Mazzo has joined the company’s board of directors. Aerie Pharmaceuticals Inc. (NASDAQ:AERI) ended the last trading day at $20.15. Company weekly volatility is calculated as 7.22% and price to cash ratio as 7.25.Aerie Pharmaceuticals Inc. (NASDAQ:AERI) showed a positive weekly performance of 15.08%.
Receptos Inc. (NASDAQ:RCPT) announced the pricing of an underwritten public offering of 4,433,000 shares of its common stock at a price to the public of $40.25 per share. The gross proceeds to Receptos from this offering are expected to be approximately $178.4 million, before deducting underwriting discounts and commissions and other estimated offering expenses. Receptos Inc. (NASDAQ:RCPT) weekly performance is 3.67%. On last trading day company shares ended up $39.86. Analysts mean target price for the company is $65.33. Receptos Inc. (NASDAQ:RCPT) distance from 50-day simple moving average (SMA50) is 20.85%.